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High-resolution capillary zone electrophoresis is used to assess the transferrin profile in 
serum of patients with eight different congenital disorders of glycosylation that represent 
type I, type II and mixed type I/II disorders. Capillary zone electrophoresis data are 
compared to patterns obtained by gel isoelectric focusing. The high-resolution capillary zone 
electrophoresis method is shown to represent an effective tool to assess the diversity of 
transferrin patterns. Hypoglycosylated disialo-, monosialo- and asialo-transferrin in type I 
cases can be distinguished from the corresponding underdesialylated transferrin glycoforms 
present in type II disorders. The latter can be separated from and are detected ahead of 
their corresponding hypoglycosylated forms of type I patients. Both types of glycoforms are 
detected in sera of mixed type I/II patients. The assay has the potential to be used as 
screening method for congenital disorders of glycosylation. It can be run with a few µL of 
serum when microvials are used. 
1 INTRODUCTION 
Transferrin (Tf) is an iron transporting glycoprotein with two iron binding sites and two N-
linked carbohydrate chains which are composed of a bi- to tetraantennary carbohydrate 
chain with terminal sialic acid residues. Due to different numbers of end standing sialic acid 
residues (zero up to eight), human serum comprises Tf isoforms which differ in their pI 
values (between 5.9 and about 5.0 after complete iron saturation) and electrophoretic 
mobilities [1,2]. Monitoring of Tf isoforms is important in clinical and forensic analysis for 
the determination of carbohydrate-deficient transferrin (CDT) which is a marker for 
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excessive alcohol intake over an extensive period of time, the elucidation of genetic 
variants, the monitoring of asialo-Tf (referred to as beta-2-Tf ) in nasal and other fluids 
which is a marker for cerebrospinal fluid leakage, and the assessment of a congenital 
disorder of glycosylation (CDG). CDGs are a group of rare recessively inherited diseases with 
severe neurological and/or systemic manifestations from early childhood [3–6]. CDGs are 
divided into two main groups: type I CDGs comprise defects in the assembly of the dolichol 
lipid-linked oligosaccharide chain and its transfer to the nascent protein and are 
characterized by unoccupied glycosylation sites on proteins, thus lacking complete N-
glycans. Type II CDGs refer to defects in the trimming and processing of the protein-bound 
glycans either late in the endoplasmic reticulum or the Golgi compartments resulting in 
immature, truncated glycans. Gel isoelectric focusing (GIEF) [1,2,7,8], gel electrophoresis [9], 
HPLC [10], CZE [11–17] and MS [18–22] are employed to measure Tf isoform distributions in 
human serum.  
CZE assays allow separation of Tf isoforms on the basis of differences in electrophoretic 
mobilities, i.e. charge/mass with the charge state being determined by the number of 
terminal sialic acid residues. They are attractive for CDG screening as they can be automated 
and require small amounts of serum only. The latter aspect, which is an important feature 
as only tiny amounts of serum can be drawn from newborns and infants, is also given in 
GIEF. Tf isoform analysis by CZE is performed with automated multicapillary platforms 
(CAPILLARYS of Sebia, Evry, France) or with the CDT reagent kit CEofix (Analis, Namur, 
Belgium) on single capillary instruments of different manufacturers [23,24]. The latter 
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system comprises polymeric polyions that form a dynamic double coating, an approach that 
leads to highly reproducible data [16] and was optimized for high-resolution analyses in our 
laboratory [17] which is advantageous for analysis of patient sera with unusual Tf patterns, 
including those with high amounts of trisialo-Tf and genetic variants [23–27]. CDG serum Tf 
patterns using the CEofix approach [11,23,28,29], the CAPILLARYS assay [30,31] and 
laboratory-made assays [32–35] have been reported. Furthermore, CZE was also used to 
determine CDG Tf patterns in extracts from Guthrie cards onto which the patient serum was 
applied [30,36]. In all these papers, few examples were discussed only with the aim of 
highlighting the use of CZE for CDG monitoring. The CZE separability of asialo-, monosialo, 
and disialo-Tf glycoforms present in sera of different types of CDG patients, particularly 
those found in mixed type I/II CDG patients, has not yet been evaluated. This is an important 
aspect for the adoption of CZE as screening method for CDG and prompted us to assess it in 
our laboratory. 
In this paper, sera of known type I, type II and mixed type I/II CDG patients (Table I) were 
analyzed by CZE employing the high-resolution CEofix based assay which is employed for 
determination of CDT with stringent quality assurance [17,36] and for identification of 
genetic variants of Tf [26,27]. This assay has a higher resolution for disialo-Tf and trisialo-Tf 
compared to the CAPILLARYS assay [25] and the CEofix assay configuration promoted by the 
manufacturer of the reagents [17]. The data were compared to those monitored by GIEF 
with an assay featuring an immobilized pH gradient.  
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2 MATERIALS AND METHODS  
2.1 Chemicals, reagents, origin of samples and preparation of samples  
The chemicals used were of analytical grade if not stated otherwise. Ferric citrate and BSA 
were purchased from Sigma–Aldrich Chemie (Schnelldorf, Germany). Polyclonal rabbit anti-
human Tf antibodies (titer: 2800 mg/L) was from Dako (Glostrup, Denmark). Buffers and 
reagents of the CEofix CDT kit No. 10-004760 were from Analis (Suarlée, Belgium). The CDT 
ClinCheck serum control level II was from Recipe (Munich, Germany) and used as control 
sample. Patient sera were received for the determination of the type of CDG (Table 1) or for 
the monitoring of CDT. CDG samples of patients 12 and 13 (Table 1) were obtained from the 
Radboudumc center of expertise for disorders of glycosylation (Nijmegen, The Netherlands). 
Our own serum was used for investigational work. All samples were stored at –20 or –70°C 
until use. Patient sera were also analyzed after immunosubtraction according to the 
procedure reported previously [17,26]. Briefly, a 1:2 v/v mixture of serum and anti-human Tf 
antibody solution was incubated for 45 min at room temperature and centrifuged at 8000 g 
and 4°C for 20 min. A 2:1 v/v mixture of supernatant aliquot and ferric solution was briefly 
vortex mixed and analyzed. 
2.2 Instrumentation and running conditions for CZE analysis  
All CZE analyses were performed on a PA800plus CE system (Beckman Coulter) according to 
Joneli et al. [17] and employed in other work from our laboratory [25,26,35,37]. Briefly, a 50 
m id fused-silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of 60.2 cm (50 cm to 
the detector) total length was used. For iron saturation, 60 L of serum and 60 L of the 
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Fe(III) containing solution of the reagent kit (Analis) were combined in a sample vial and 
briefly mixed as described before [17]. Alternatively, nanoVials (Sciex, Framingham, MA, 
USA) were used for which the amount of serum and Fe(III) reagent could be reduced to 5 µL 
each. Samples were injected by vacuum (12 s at 0.5 psi, 1 psi = 6894.76 Pa) and were 
analyzed at a capillary cartridge temperature of 30.0°C, an applied voltage of 20.0 kV and 
having a detection wavelength of 200 nm (interference filter). Instrument control and peak 
integration were performed with the 32 Karat software (Beckman Coulter). Peak areas were 
determined by valley-to-valley integration and the data were evaluated on the basis of 
corrected peak areas (peak area divided by migration time).  
2.3 Instrumentation and running conditions for isoelectric focusing 
GIEF analyses were made as described previously [38]. Briefly, serum Tf was saturated for 30 
min with ferric citrate (0.4 mM) in the presence of sodium hydrogen carbonate (20 mM) and 
separated on a rehydrated Immobiline DryPlate gel (GE Healthcare Life Sciences, Glattbrugg, 
Switzerland) with a pH range of 4.0–7.0 using the PhastSystem of Amersham Biosciences 
(GE Healthcare Life Sciences). Tf was visualized by gel immunoprecipitation using polyclonal 
rabbit anti-human Tf antibodies (Dako). The antibody solution was directly applied onto the 
gel and incubated for 1 h. To remove excess antibodies and non-bound proteins, the gel was 
washed overnight in 0.9% NaCl followed by fixation and staining with Phast-Gel Blue R (GE 
Healthcare Life Sciences) according to the manufacturer’s protocol. 
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3 RESULTS AND DISCUSSION 
High-resolution CZE is routinely employed for the determination of CDT in human serum 
[17,37] and the monitoring of genetic variants [26,27]. The assay comprises mixing of 
human serum with a Fe(III) ion-containing solution before the analysis of the iron-saturated 
mixture in a dynamically double coated capillary using a commercial buffer at alkaline pH. 
For sera with very small amounts of Tf and in case of interferences with other compounds, 
Tf has to be immunoextracted before analysis [39]. This high-resolution assay was now used 
to monitor Tf isoform patterns in sera of CDG patients. Immunosubtraction of Tf and 
reanalysis of the supernatant revealed the peaks in the electropherograms that are 
associated with Tf. Furthermore, identification of isoform patterns is accomplished by 
comparison of migration times with those of a commercial serum control and/or with 
spiking the unknown sample with a serum of a healthy individual, an alcohol abuser or a 
patient and reanalysis of the mixture. The amounts of single Tf isoforms are calculated as 
area % in relation to the sum of the corrected peak areas of all detected Tf isoforms. The Tf 
isoform pattern in normal healthy subjects comprises disialo-Tf (< 1.7%), trisialo-Tf (about 
4%), tetrasialo-Tf isoform (about 80%), pentasialo-Tf (about 14%) and hexasialo-Tf (about 
1%). Other isoforms are not detected. Following excessive alcohol ingestion for extended 
time periods, the amounts of less glycosylated forms of Tf (disialo-Tf > 2%, monosialo-Tf and 
asialo-Tf) are increasing. Less glycosylated forms of Tf are also found in sera of CDG patients 
[23,24,28–34], CSF [24] and can be produced in vitro by addition of neuraminidase to serum 
[16]. 
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The precision performance in regard to migration times of Tf isoforms and quantification of 
single Tf isoforms and CDT was evaluated with the ClinCheck level II control serum 
comprising an asialo-Tf level of about 0.4% and a disialo-Tf amount of about 3.0% and 
regular sample vials comprising 60 L of serum and 60 L of the Fe(III) solution. RSD values 
(n=10) for the intraday repeatability of migration times of all Tf peaks were found to be < 
0.25%. Corresponding values for the interday data were between 0.33 and 1.09%. RSD 
values for the quantitative determination of the Tf isoforms were between 1.37 (tetrasialo-
Tf, glycoforms with highest level) and 13.02% (asialo-Tf, glycoforms with lowest level). The 
limits of isoform quantification and detection were determined to be 0.10 and 0.05%, 
respectively [17]. Using nanoVials instead of regular sample vials, for which the amount of 
serum and Fe(III) reagent solution could be reduced to 5 µL each, indistinguishable Tf data 
were obtained. These data document the excellent precision of the assay. 
3.1 CZE analysis of transferrin isoforms in sera of type-Ia patients  
The graphs presented in Fig. 1 depict electropherograms obtained with the sera of two 
patients with phosphomannomutase 2 (PMM2) deficiency which is also referred to as CDG 
type Ia. PMM2-CDG is an inherited condition with a defect in the second step of the 
mannose pathway that affects many parts of the body. The type and severity of problems 
associated with PMM2-CDG vary widely among affected individuals, sometimes even among 
members of the same family [3]. As shown previously with the serum of another patient 
[23], PMM2-CDG Tf patterns are substantially different compared to those monitored with 
the serum of healthy subjects and alcohol abusers. The patterns are characterized with 
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substantial peaks for asialo-Tf, disialo-Tf, tetrasialo-Tf and penta-sialo-Tf (Fig. 1). The 
magnitude of the tetrasialo-Tf peak is much smaller than that of a normal subject. It can be 
smaller [23], about equal (Fig. 1A) or larger (Fig. 1B) compared to the disialo-Tf peak. These 
data compare well with the GIEF results shown as inserts in the panels of Fig. 1. 
Furthermore, the migration times for asialo-Tf, disialo-Tf, tetrasialo-Tf and penta-sialo-Tf are 
the same as those observed with the control sample (upper graphs in panels A and B of Fig. 
1). The commercial ClinCheck serum level II used as control sample has a small asialo-Tf 
peak and an elevated disialo-Tf peak and represents a pattern typically observed with sera 
of alcohol abusers [17,37]. The data suggest that the glycoforms detected in sera of PMM2-
CDG patients are those observed in alcohol abusers and healthy individuals. This is in 
agreement with the data of intact Tf molecules obtained by LC–ESI-MS [18–20], HPLC–chip-
QTOF [21] and CZE–ESI-MS [34]. CZE analyses of mixtures comprising sera of PMM2-CDG 
patients and alcohol abusers revealed the same result (Fig. 1C). Analysis of a mixture of 
small aliquots of the PMM2-CDG samples 1 to 5 (Table 1) resulted in an electropherogram 
(graph I of Fig. 1C) similar to those shown in Fig. 1A and 1B. This demonstrates that all 
corresponding Tf-isoforms in the mixed PMM2-CDG sera comigrate. The data obtained with 
the serum of an alcohol abuser which exhibits an asialo-Tf peak and a small monosialo-Tf 
peak is depicted as graph II in Fig. 1C. Analysis of the mixture of the PMM2-CDG sera with 
that of the alcohol abuser (graph III of Fig. 1C) suggest that asialo-Tf and disialo-Tf 
glycoforms in these samples are indeed comigrating and could thus be identical. MS 
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analyses confirmed their identity and revealed that asialo-Tf lacks both whereas disialo-Tf 
one of the two carbohydrate chains [18–21,34]. 
The amount of trisialo-Tf in the pattern of PMM2-CDG patients is much smaller compared to 
healthy individuals and alcohol abusers. The CZE data presented in Fig. 1 are characterized 
with an unresolved double peak (Fig. 1A and 1C) or a broad peak (Fig. 1B) for trisialo-Tf. It 
appears that two different molecules are formed which cannot be distinguished in GIEF 
(same pI values) but exhibit slightly different effective mobilities under the conditions used 
for CZE. Such double peaks are typically not observed in patient sera of alcohol abusers as 
well as in sera of healthy individuals (graph IV of Fig. 1C). The data revealed that trisialo-Tf 
found in the serum of the alcohol abuser corresponds to the first part of the trisialo-Tf peak 
monitored in the samples of PMM2-CDG patients (graph III of Fig. 1C). The same was found 
to be true for trisialo-Tf of a healthy subject (graph IV of Fig. 1C). Complete separation of the 
two peaks would require an assay of higher resolution. It is interesting to note that large 
and broad trisialo-Tf peaks that can even overlap the disialo-Tf peak are occasionally 
observed for sera of patients with liver cirrhosis. This situation is referred to as disialo-
trisialo-Tf bridging and was reported to be a result of increased branching and fucosylation 
of the carbohydrate moiety [24,40]. Furthermore, sera of PMM2-CDG patients also contain 
small amounts of monosialo-Tf (Fig. 1). The concentration of this isoform, however, is too 
small to produce reliable peaks.  
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3.2 Diversity of Tf patterns of type I patients  
The α-1,3-glucosyltransferase (ALG6)-CDG (previously called CDG Ic) is a defect in N-glycan 
assembly in the endoplasmic reticulum and is, after PMM2-CDG, the second most common 
type of CDG [41,42]. Analysis of the serum of an ALG6-CDG patient revealed a CZE pattern 
that is essentially identical to that of PMM2 (Fig 2A). The same was found to be true for a 
serum of a patient with a steroid 5α-reductase type 3 deficiency (Fig. 2B) referred to as 
SRD5A3-CDG or CDG-Iq [43] and pattern similarity is in agreement with the data obtained by 
ESI-MS [20]. 
The data presented in Fig. 3A were obtained with the serum of an ALG13-CDG (CDG-Is) 
patient. ALG13-CDG is a CDG-I subtype with a near-normal glycosylation such that diagnosis 
of ALG13-CDG with GIEF can be missed if genetic studies are not performed [44]. The 
electropherogram shows an asialo-Tf peak (0.91% of total Tf) and an elevated disialo-Tf peak 
(7.74%). This Tf profile has a higher level of disialo-Tf compared to trisialo-Tf which is 
different than in the control sample used (Fig. 3A). The disialo-Tf levels in the sera of alcohol 
abusers can be lower, equal or higher than trisialo-Tf [23,24,17]. Thus, the ALG13-CDG 
pattern shown in Fig. 3A cannot be distinguished from that of an alcohol abuser. Migration 
times of all isoforms are identical to those of the control (upper graph of Fig. 3A). ALG11-
CDG (CDG Ip) is another CDG-I subtype and as shown in Fig. 3B, a disialo-Tf peak of 6.44% of 
total Tf was monitored which is much higher than in a healthy individual. The 
electropherogram of Fig. 3B does not reveal the presence of an asialo-Tf that could be 
quantified. This is somewhat different compared to the sera of alcohol abusers for which an 
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asialo-Tf peak is typically monitored when the disialo-Tf peak is larger than 3.0% [24,45]. 
Migration times of the Tf isoforms monitored in panels 3A and 3B were identical. 
3.3 Transferrin patterns of type II patients  
The data presented in Fig. 4A were obtained with a serum of a MGAT2-CDG (CDG type IIa; 
sample 8 of Table 1) patient. The monitored Tf pattern is completely different compared to 
those of CDG type I patients. It comprises a peak for disialo-Tf and a broad peak tentatively 
assigned to trisialo-Tf (Fig. 4A). This pattern is consistent with that obtained by GIEF (insert 
in Fig. 4A). Comparison with the control sample (upper graph in Fig. 4A) revealed that 
disialo-Tf in the case of MGAT2-CDG was detected earlier than in the control sample and the 
PMM2-CDG sera. This was confirmed by analysis of a mixture of the CDG sample and the 
serum of an alcohol abuser (compare graph III with graphs I and II of Fig. 4C). Disialo-Tf 
detected in the serum of the MGAT2-CDG patient was thus labeled with an asterisk. It 
represents a Tf isoform with both carbohydrate chains bearing one terminal sialic acid 
residue which is in contrast to disialo-Tf that has one carbohydrate chain with two sialic acid 
residues [18]. The latter is found in sera of CDG type I patients, alcohol abusers and healthy 
individuals [18,21] whereas the former in CDG type II patients [18,34]. The two disialo-Tf 
isoforms have the same charge, but differ in mass and thus in electrophoretic mobility. The 
compound with two carbohydrate chains is detected before that with one chain because it 
has a larger mass and thus lower electrophoretic mobility. Evidence for this behavior was 
previously reported by Sanz-Nebot et al. [34]. The monitored Tf pattern is in principle 
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comparable to that obtained by low resolution CZE assays [11]. With the latter assay format, 
however, it is not possible to sense the difference of the two disialo-Tf molecules. 
COG5-CDG, also known as CDG type IIi, is an extremely rare form of a CDG syndrome [46]. 
Analysis of the serum of such a patient (patient 6 of Table 1) revealed the pattern shown in 
Fig. 4B. The first detected disialo-Tf peak (peak 2*) was found to comigrate with that of the 
MGAT2-CDG patient sample (compare graphs IV and VI of Fig. 4C). Furthermore, at the time 
interval of disialo-Tf found in alcohol abusers and healthy individuals, a small peak was 
monitored (peak 2 in graphs IV to VI of Fig. 4C). Compared to a healthy subject, it revealed a 
higher amount of disialo-Tf (4.26% instead of < 1.70% for the sum of peaks 2 and 2*) and a 
much higher amount of trisialo-Tf (22.1% instead of 3–5% of total Tf). GIEF analysis revealed 
the presence of disialo-, trisialo-, tetrasialo- and pentasialo-Tf (insert in Fig. 4B). 
Furthermore, the GIEF data revealed a pattern with double bands indicating that this person 
is a Tf-CC heterozygote whose isoforms could not be resolved by CZE (for other examples of 
such genetic variants see [26,27]). 
MGAT2- and COG5-CDG belong to the type II CDG group leading to truncated N-glycans. 
Disialo-Tf marked with an asterisk (peak 2*) is a result of undersialylated glycans, whereas 
disialo-Tf (peak 2) deriving from PMM2 patients (type I CDG) represents hypoglycosylated Tf 
due to an unoccupied N-glycosylation site. It is therefore concluded that high-resolution CZE 
is able to distinguish between hypoglycosylated and undersialylated disialo-Tf. 
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3.4 Transferrin patterns of mixed type I/II patients  
PGM1-CDG results from deficiencies in phosphoglucomutase 1 and combines glycosylation 
abnormalities found in CDG type I and CDG type II [47]. This is documented with the CZE 
data presented in Fig. 5A that shows an electropherogram obtained with the serum of a 
PGM1-CDG patient (sample 11 of Table 1). It reveals peaks for asialo-Tf, monosialo-Tf, 
disialo-Tf, trisialo-Tf, tetrasialo-Tf and pentasialo-Tf. The same isoforms were detected by 
GIEF (insert in Fig. 5A). As for the example of Fig. 4B, the GIEF data show double bands, 
indicating that it represents a heterozygote Tf-CC variant. The CZE data exhibit two peaks for 
asialo-Tf, monosialo-Tf and disialo-Tf, but not for the other isoforms (graph I of Fig. 5B). 
Peaks labeled without asterisk correspond to those detected in alcohol abusers and CDG 
type I patients (Figs. 1C and 5B). Furthermore, this serum also exhibits peaks for Tf isoforms 
with undersialylated glycans (peaks marked with asterisk), namely disialo-Tf (peak 2*) that 
was found in the sera of CDG type II samples shown in Fig. 4, and corresponding peaks for 
monosialo-Tf and asialo-Tf. These findings are in agreement with the MS analysis of intact Tf 
molecules reported by Tegtmeyer et al. [47] and Van Scherpenzeel et al. [21]. In the high-
resolution CZE assay, all three compounds with undersialylated glycans are detected before 
those with hypoglycosylation. For trisialo-Tf, the PGM1-CDG data (Fig. 5A) and the COG5-
CDG electropherogram (Fig. 4B) show a normal peak and not a double or broad peak as was 
observed for PMM2-CDG (Fig. 1). According to the migration time, it corresponds to trisialo-
Tf monitored with the control sample (upper graphs in Figs. 4B and 5A) and the serum of an 
alcohol abuser (Fig. 4C and 5B).  
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A sample from a patient diagnosed with liver cirrhosis, various carcinomas, Parkinson’s 
disease and diabetes mellitus type 2 that was analyzed in the context of CDT monitoring by 
CZE exhibited unusual desialylated Tf glycoforms [17]. This serum comprised different 
asialo-Tf, monosialo-Tf and disialo-Tf peaks compared to those of alcohol abusers (Fig. 6A, 
Fig. 6B with graphs I to III). These peaks were found to comigrate with the three Tf isoforms 
with undersialylated glycans present in the PGM1-CDG sample of Fig. 5 (Fig. 6B, compare 
graphs I and IV, peaks marked with asterisks). Thus, it can be hypothesized that this serum is 
more likely stemming from a patient with a secondary cause of abnormal glycosylation 
rather than a type I/II CDG disorder. Hyposialylated Tf glycoforms appear to be present in 
patients with liver diseases. The occurrence, however, is rare as only samples of two 
patients with such a transferrin pattern were analyzed in a 10-year period during which a 
total of about 4500 samples from the hepatology outpatient clinic were analyzed. Such 
hyposialylated Tf glycoforms are also characteristic for sera with neuraminidase activity, 
including those of patients with hemolytic uremic syndrome associated with a Streptococcus 
pneumoniae infection [47,48]. 
4 CONCLUDING REMARKS 
The high-resolution CZE assay was used to resolve Tf glycoforms of similar structure. Under 
the described conditions, hypoglycosylated Tf glycoforms of CDG type I and undersialylated 
Tf glycoforms of CDG type II can be distinguished. For disialo-Tf, monosialo-Tf and asialo-Tf, 
undersialylated glycoforms are detected ahead of their corresponding hypoglycosylated 
forms because they have a higher molecular mass and thus a lower electrophoretic mobility. 
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The serum of a PGM1-CDG patient is shown to comprise both hypoglycosylated Tf 
glycoforms found in CDG type I and undersialylated glycoforms of CDG type II. The CZE data 
indicate that Tf glycoforms monitored in CDG type I samples comigrate with those observed 
in sera of alcohol abusers. This is in agreement with the MS literature which reports the 
identity of the glycoforms in these samples [18–21,34]. Most of the monitored Tf profiles of 
CDG patients are different to those of alcohol abusers or normal subjects and thus provide a 
mean to recognize the presence of a CDG. The data obtained reveal that the Tf profiles of 
ALG6-CDG and SRD5A3-CDG patients are the same as those monitored for PMM2-CDG. The 
ALG13-CDG sample comprises a Tf glycoform distribution that cannot be distinguished from 
that of an alcohol abuser. The high-resolution CZE assay has the potential to be used as 
screening method for CDGs. It can be run with a few µL of serum when samples are applied 
with nanoVials. This is an important feature as only tiny amounts of serum can be drawn 
from newborns and infants. This aspect was pointed out previously for CDT analysis by CZE 
in samples of healthy newborns [49]. Furthermore, hyposialylated Tf glycoforms detected in 
the serum of a patient with liver cirrhosis and other diseases revealed the same 
electrophoretic behavior as those of the serum of a PGM1-CDG patient. 
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Table 1. CDG samples analyzed 
     
     Patient 
sample 
number 
Affected gene locus Function Nucleotide and/or AA changes Disease 
  (MIM # )   Allele1/allele 2   
1 PMM2 (601785) Phosphomannomutase P119L/R141H PMM2-CDG (CDG-Ia) 
2 PMM2 (601785) Phosphomannomutase P113L/F157S PMM2-CDG (CDG-Ia) 
3 PMM2 (601785) Phosphomannomutase T237R/L243P PMM2-CDG (CDG-Ia) 
4 PMM2 (601785) Phosphomannomutase R141H/L243P PMM2-CDG (CDG-Ia) 
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5 PMM2 (601785) Phosphomannomutase F157S/E197A PMM2-CDG (CDG-Ia) 
6 COG5 (606821) Conserved oligomeric Golgi (COG) complex c.1669-15T>C/c.1669-15T>C COG5-CDG (CDG-IIi) 
7 PMM2 (601785) Phosphomannomutase c.647A>T (p.N216I)/c.640-9T>G PMM2-CDG (CDG-Ia) 
8 MGAT2 (602616) β1–2 GlcNAc-transferase c.1085G>A (W362X)/c.1085G>A (W362X) MGAT2-CDG (CDG-IIa) 
9 ALG 13 (300884) 
UDP-N-acetylglucosaminyltransferase 
subunit 
mutation not given ALG13-CDG (CDG-Is) 
10 ALG 11 (613666) α1–2 man-transferase mutation not given ALG11-CDG (CDG-Ip) 
11 PGM1 (614921) Phosphoglucomutase mutation not given PGM1-CDG (CDGI/II) 
12 ALG6 (604566) α1–3 Glc-transferase IVS 3+5 g>a ALG6-CDG (CDG-Ic) 
13 SRD5A3 (611715) Polyprenol reductase c.29 C>A; p.Ser10X SRD5A3-CDG (CDG-Iq) 
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Legends 
Figure 1. CZE electropherograms obtained with the sera of two PMM2-CDG patients. The 
central graphs are from (A) patient 3 and (B) patient 7 of Table 1. The upper graphs depict 
data of the commercial control serum with an elevated CDT level and the dashed line graphs 
were obtained after immunosubtraction of Tf from the patient sera. The inserts depict GIEF 
data. Panel C presents data of a pool of PMM2-CDG patient sera (samples 1–5 of Table 1, 
graph I), a serum of an alcohol abuser (graph II), a 1:2 v/v mixture of the PMM2-CDG patient 
pool and the alcohol abuser (graph III), and the serum of a healthy individual (graph IV). 
Asialo-Tf, monosialo-Tf, disialo-Tf, trisialo-Tf, tetrasialo-Tf, pentosialo-Tf and hexasialo-Tf are 
referred to with the numbers 0, 1, 2, 3, 4, 5 and 6, respectively. EO refers to the EOF. 
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Figure 2. CZE electropherograms obtained with the sera of (A) an ALG6-CDG patient (sample 
12 of Table 1) and (B) a SRD5A3-CDG patient (sample 13 of Table 1). Other conditions and 
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Figure 3. CZE electropherograms obtained with the sera of (A) an ALG13-CDG patient 
(sample 9 of Table 1) and (B) an ALG11-CDG patient (sample 10 of Table 1). Other conditions 
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Figure 4. CZE electropherograms obtained with the sera of (A) a MGAT2-CDG patient 
(sample 8 of Table 1) and (B) a COG5-CDG patient (sample 6 of Table 1). Panel C depicts data 
of the MGAT2-CDG serum (graph I), an alcohol abuser (graph II), a 1:1 v/v mixture of the 
sera of the MGAT2-CDG patient and the alcohol abuser (graph III), the COG5-CDG patient 
(graph IV), a 1:1 v/v mixture of the sera of the COG5-CDG patient and the alcohol abuser 
(graph V), and a 2:1 v/v mixture of the sera of the COG5-CDG and MGAT2-CDG patients 
(graph VI). Other conditions and key as for Fig. 1. The peaks marked with an asterisk are 
desialylated disialo-Tf of CDG type II with has two carbohydrate moieties featuring one sialic 
acid each. 
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Figure 5. (A) CZE data obtained with the serum of a PGM1-CDG patient (sample 11 of Table 
1) together with the electropherograms obtained after immunosubtraction of Tf in the 
patient serum (dashed line graph) and the commercial control serum. (B) Data of the PGM1-
CDG patient sample (graph I), a serum of an alcohol abuser (graph II) and a 1:1 v/v mixture 
of the sera of the patient and the alcohol abuser (graph III). The peaks marked with asterisks 
are desialylated Tf glycoforms comprising both carbohydrate chains. Other conditions and 
key as for Fig. 4. 
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Figure 6: (A) Data of a patient serum with unusual desialylated Tf isoforms (graph I) together 
with the electropherogram obtained after immunosubtraction of Tf in the patient serum 
(dashed line graph), the serum of an alcohol abuser (graph III) and a 1:1 mixture of the sera 
of the patient and the alcohol abuser (graph II). (B) Data of the patient serum (graph I), 
another alcohol abuser (graph II), the 1: 1 v/v mixture of the patient and the alcohol abuser 
(graph III) and a 1:2 v/v mixture of the patient serum with that of the PGM1-CDG patient of 
Fig. 5 (graph IV). Key as for Fig. 5. For further explanations refer to text. 
 
 
 
